Innoviva Income After Taxes 2012-2026 | INVA
Innoviva income after taxes from 2012 to 2026. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
|
Innoviva Annual Income After Taxes (Millions of US $) |
|
|---|---|
| 2025 | $271 |
| 2024 | $23 |
| 2023 | $180 |
| 2022 | $220 |
| 2021 | $369 |
| 2020 | $294 |
| 2019 | $191 |
| 2018 | $406 |
| 2017 | $134 |
| 2016 | $60 |
| 2015 | $-19 |
| 2014 | $-74 |
| 2013 | $-31 |
| 2012 | $-31 |
| 2011 | $-115 |
|
Innoviva Quarterly Income After Taxes (Millions of US $) |
|
|---|---|
| 2026-03-31 | $187 |
| 2025-12-31 | $164 |
| 2025-09-30 | $90 |
| 2025-06-30 | $64 |
| 2025-03-31 | $-47 |
| 2024-12-31 | $20 |
| 2024-09-30 | $1 |
| 2024-06-30 | $-35 |
| 2024-03-31 | $37 |
| 2023-12-31 | $62 |
| 2023-09-30 | $82 |
| 2023-06-30 | $1 |
| 2023-03-31 | $35 |
| 2022-12-31 | $-68 |
| 2022-09-30 | $229 |
| 2022-06-30 | $21 |
| 2022-03-31 | $38 |
| 2021-12-31 | $46 |
| 2021-09-30 | $103 |
| 2021-06-30 | $111 |
| 2021-03-31 | $110 |
| 2020-12-31 | $75 |
| 2020-09-30 | $42 |
| 2020-06-30 | $98 |
| 2020-03-31 | $79 |
| 2019-12-31 | $58 |
| 2019-09-30 | $47 |
| 2019-06-30 | $46 |
| 2019-03-31 | $40 |
| 2018-12-31 | $269 |
| 2018-09-30 | $50 |
| 2018-06-30 | $57 |
| 2018-03-31 | $30 |
| 2017-12-31 | $59 |
| 2017-09-30 | $24 |
| 2017-06-30 | $35 |
| 2017-03-31 | $17 |
| 2016-12-31 | $25 |
| 2016-09-30 | $15 |
| 2016-06-30 | $15 |
| 2016-03-31 | $4 |
| 2015-12-31 | $4 |
| 2015-09-30 | $-5 |
| 2015-06-30 | $-8 |
| 2015-03-31 | $-11 |
| 2014-12-31 | $-16 |
| 2014-09-30 | $-21 |
| 2014-06-30 | $-20 |
| 2014-03-31 | $-16 |
| 2013-12-31 | $18 |
| 2013-09-30 | $-9 |
| 2013-06-30 | $-2 |
| 2013-03-31 | $-37 |
| 2012-12-31 | $-31 |
| 2012-09-30 | $-35 |
| 2012-06-30 | $-37 |
| 2012-03-31 | $85 |
| 2011-12-31 | $-37 |
| 2011-09-30 | $-31 |
| 2011-06-30 | $-25 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |